This study is testing alirocumab (Praluent), a cholesterol-lowering medicine, in people who are on stable dialysis. We want to see how well alirocumab lowers "bad" cholesterol (LDL cholesterol) and if it is safe for people with kidney disease who are on dialysis. You might be able to join if you are between 18 and 80 years old, are on hemodialysis or peritoneal dialysis, and have high cholesterol. The study will measure your cholesterol levels over 12 weeks. The current status of this study is unclear.

Study design

This is an open-label, nonrandomized study involving 20 participants (10 on hemodialysis and 10 on peritoneal dialysis). It is not specified which phase the study is in.

What's involved

You would receive alirocumab injections under your skin every two weeks for 12 weeks. You will have blood tests at the start, and at weeks 4, 8, 10, and 12 to check cholesterol levels and other markers.

Compensation

Not stated in the trial record.

Follow-up

Your cholesterol levels will be measured at 4, 8, and 12 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.